These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Comparison of murine nasal-associated lymphoid tissue and Peyer's patches. Heritage PL; Underdown BJ; Arsenault AL; Snider DP; McDermott MR Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1256-62. PubMed ID: 9351630 [TBL] [Abstract][Full Text] [Related]
50. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Wahid R; Simon R; Zafar SJ; Levine MM; Sztein MB Clin Vaccine Immunol; 2012 Jun; 19(6):825-34. PubMed ID: 22492745 [TBL] [Abstract][Full Text] [Related]
51. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit. Walker MJ; Rohde M; Timmis KN; Guzmán CA Infect Immun; 1992 Oct; 60(10):4260-8. PubMed ID: 1398937 [TBL] [Abstract][Full Text] [Related]
52. Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin. Kohler JJ; Pathangey LB; Gillespie SR; Brown TA Infect Immun; 2000 Jun; 68(6):3116-20. PubMed ID: 10816452 [TBL] [Abstract][Full Text] [Related]
53. Cellular immunity against Salmonella typhi after live oral vaccine. Tagliabue A; Nencioni L; Caffarena A; Villa L; Boraschi D; Cazzola G; Cavalieri S Clin Exp Immunol; 1985 Nov; 62(2):242-7. PubMed ID: 3878744 [TBL] [Abstract][Full Text] [Related]
54. The development of oral vaccines against parasitic diseases utilizing live attenuated Salmonella. Chatfield SN; Roberts M; Dougan G; Hormaeche C; Khan CM Parasitology; 1995; 110 Suppl():S17-24. PubMed ID: 7784125 [TBL] [Abstract][Full Text] [Related]
55. Transcutaneous Vaccination with Conjugate Typhoid Vaccine Vi-DT Induces Systemic, Mucosal, and Memory Anti-Polysaccharide Responses. Bhuiyan MS; Kalsy A; Arifuzzaman M; Charles RC; Harris JB; Calderwood SB; Qadri F; Ryan ET Am J Trop Med Hyg; 2020 Sep; 103(3):1032-1038. PubMed ID: 32720632 [TBL] [Abstract][Full Text] [Related]
56. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. DiPetrillo MD; Tibbetts T; Kleanthous H; Killeen KP; Hohmann EL Vaccine; 1999 Oct; 18(5-6):449-59. PubMed ID: 10519934 [TBL] [Abstract][Full Text] [Related]
57. Host and bacterial factors affecting induction of immune responses to flagellin expressed by attenuated Salmonella vaccine strains. Sbrogio-Almeida ME; Mosca T; Massis LM; Abrahamsohn IA; Ferreira LC Infect Immun; 2004 May; 72(5):2546-55. PubMed ID: 15102762 [TBL] [Abstract][Full Text] [Related]
58. Salmonella Typhi outer membrane protein STIV is a potential candidate for vaccine development against typhoid and paratyphoid fever. Das S; Chowdhury R; Pal A; Okamoto K; Das S Immunobiology; 2019 May; 224(3):371-382. PubMed ID: 30952553 [TBL] [Abstract][Full Text] [Related]
59. Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vindurampulle CJ; Cuberos LF; Barry EM; Pasetti MF; Levine MM Vaccine; 2004 Sep; 22(27-28):3744-50. PubMed ID: 15315855 [TBL] [Abstract][Full Text] [Related]
60. A new intra-NALT route elicits mucosal and systemic immunity against Moraxella catarrhalis in a mouse challenge model. Hou Y; Hu WG; Hirano T; Gu XX Vaccine; 2002 May; 20(17-18):2375-81. PubMed ID: 12009294 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]